Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Cash from Financing Activities: 2022-2025

Historic Cash from Financing Activities for Phathom Pharmaceuticals (PHAT) over the last 2 years, with Sep 2025 value amounting to -$271,000.

  • Phathom Pharmaceuticals' Cash from Financing Activities fell 100.22% to -$271,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $147.9 million, marking a year-over-year decrease of 59.89%. This contributed to the annual value of $182.8 million for FY2024, which is 50.28% down from last year.
  • According to the latest figures from Q3 2025, Phathom Pharmaceuticals' Cash from Financing Activities is -$271,000, which was down 438.75% from $80,000 recorded in Q2 2025.
  • In the past 5 years, Phathom Pharmaceuticals' Cash from Financing Activities ranged from a high of $212.0 million in Q4 2023 and a low of -$271,000 during Q3 2025.
  • Moreover, its 3-year median value for Cash from Financing Activities was $19.4 million (2023), whereas its average is $55.0 million.
  • Per our database at Business Quant, Phathom Pharmaceuticals' Cash from Financing Activities surged by 938,800.00% in 2024 and then plummeted by 100.22% in 2025.
  • Phathom Pharmaceuticals' Cash from Financing Activities (Quarterly) stood at $24.6 million in 2022, then crashed by 99.95% to $212.0 million in 2023, then tumbled by 87.71% to $26.0 million in 2024, then plummeted by 100.22% to -$271,000 in 2025.
  • Its last three reported values are -$271,000 in Q3 2025, $80,000 for Q2 2025, and $26.0 million during Q4 2024.